Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C

Journal of Hepatology

Volumn 62, Issue 1, 2015, Pages 18-23

  Simon, Tracey G ^a,c   King, Lindsay Y ^b,c   Zheng, Hui ^b,c   Chung, Raymond T ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cirrhosis; Hepatitis C virus; Lipid lowering agent

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VIRUS DNA;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE COURSE; FATTY LIVER; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ISHAK FIBROSIS SCORE; LIVER BIOPSY; LIVER FIBROSIS; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCORING SYSTEM; THROMBOCYTE COUNT; TREATMENT OUTCOME; BIOPSY; DRUG EFFECTS; FOLLOW UP; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; VIROLOGY;

BIOPSY; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 84918578495     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.08.013     Document Type: Article

References (49)

1. G.L. Armstrong, A. Wasley, E.P. Simard, G.M. McQuillan, W.L. Kuhnert, and M.J. Alter The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 2006 705 714
2. D.L. Thomas, and L.B. Seeff Natural history of hepatitis C Clin Liver Dis 9 2005 383 398 vi
3. T. Kisseleva, and D.A. Brenner Anti-fibrogenic strategies and the regression of fibrosis Best Pract Res Clin Gastroenterol 25 2011 305 317
4. M.F. Demierre, P.D. Higgins, S.B. Gruber, E. Hawk, and S.M. Lippman Statins and cancer prevention Nat Rev Cancer 5 2005 930 942
5. T.M. Welzel, B.I. Graubard, S. Zeuzem, H.B. El-Serag, J.A. Davila, and K.A. McGlynn Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database Hepatology 54 2011 463 471
6. S. Bonovas, K. Filioussi, N. Tsavaris, and N.M. Sitaras Statins and cancer risk: a literature-based meta-Analysis and meta-regression analysis of 35 randomized controlled trials J Clin Oncol 24 2006 4808 4817
7. S. Singh, P.P. Singh, A.G. Singh, M.H. Murad, and W. Sanchez Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-Analysis Gastroenterology 144 2013 323 332
8. J. Kuoppala, A. Lamminpaa, and E. Pukkala Statins and cancer: a systematic review and meta-Analysis Eur J Cancer 44 2008 2122 2132
9. R. Kalluri, and E.G. Neilson Epithelial-mesenchymal transition and its implications for fibrosis J Clin Invest 112 2003 1776 1784
10. T. Kisseleva, and D.A. Brenner Mechanisms of fibrogenesis Exp Biol Med 233 2008 109 122
11. D. Schuppan, and N.H. Afdhal Liver cirrhosis Lancet 371 2008 838 851
12. K. Iwaisako, D.A. Brenner, and T. Kisseleva What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis J Gastroenterol Hepatol 27 2012 65 68
13. H. Shirin, E. Sharvit, H. Aeed, D. Gavish, and R. Bruck Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats World J Gastroenterol 19 2013 241 248
14. H.Y. Sun, and N. Singh Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients Clin Infect Dis 48 2009 745 755
15. J. Wu, W.W. Wong, F. Khosravi, M.D. Minden, and L.Z. Penn Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis Cancer Res 64 2004 6461 6468
16. S. Rao, D.C. Porter, X. Chen, T. Herliczek, M. Lowe, and K. Keyomarsi Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase Proc Natl Acad Sci U S A 96 1999 7797 7802
17. J. Trebicka, M. Hennenberg, M. Odenthal, K. Shir, S. Klein, and M. Granzow Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells J Hepatol 53 2010 702 712
18. T. Miyaki, S. Nojiri, N. Shinkai, A. Kusakabe, K. Matsuura, and E. Iio Pitavastatin inhibits hepatic steatosis and fibrosis in non-Alcoholic steatohepatitis model rats Hepatol Res 41 2011 375 385
19. M. Marcelli, G.R. Cunningham, S.J. Haidacher, S.J. Padayatty, L. Sturgis, and C. Kagan Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP Cancer Res 58 1998 76 83
20. A.L. Avins, M.M. Manos, L. Ackerson, W. Zhao, R. Murphy, and T.R. Levin Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study Drug Saf 31 2008 325 334
21. L.M. Henderson, S. Patel, T.P. Giordano, L. Green, and H.B. El-Serag Statin therapy and serum transaminases among a cohort of HCV-infected veterans Dig Dis Sci 55 2010 190 195
22. J.H. Lewis, M.E. Mortensen, S. Zweig, M.J. Fusco, J.R. Medoff, and R. Belder Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial Hepatology 46 2007 1453 1463
23. A.M. Di Bisceglie, M.L. Shiffman, G.T. Everson, K.L. Lindsay, J.E. Everhart, and E.C. Wright Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon N Engl J Med 359 2008 2429 2441
24. K. Ishak, A. Baptista, L. Bianchi, F. Callea, J. De Groote, and F. Gudat Histological grading and staging of chronic hepatitis J Hepatol 22 1995 696 699
25. M.G. Ghany, A.S. Lok, J.E. Everhart, G.T. Everson, W.M. Lee, and T.M. Curto Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C Gastroenterology 138 2010 136 146
26. A.B. Siegel An ounce of prevention is better than a pound of cure: a patient-centered approach to hepatocellular carcinoma J Clin Oncol 31 2013 1499 1501
27. V. Hernandez-Gea, and S.L. Friedman Pathogenesis of liver fibrosis Annu Rev Pathol 6 2011 425 456
28. A. Mallat, A.M. Preaux, S. Blazejewski, D. Dhumeaux, J. Rosenbaum, and P. Mavier Effect of simvastatin, an inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells Hepatology 20 1994 1589 1594
29. G.B. Atkins, and M.K. Jain Role of Kruppel-like transcription factors in endothelial biology Circ Res 100 2007 1686 1695
30. Z. Lin, A. Kumar, S. SenBanerjee, K. Staniszewski, K. Parmar, and D.E. Vaughan Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function Circ Res 96 2005 e48 e57
31. S. SenBanerjee, Z. Lin, G.B. Atkins, D.M. Greif, R.M. Rao, and A. Kumar KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation J Exp Med 199 2004 1305 1315
32. G. Marrone, L. Russo, E. Rosado, D. Hide, G. Garcia-Cardena, and J.C. Garcia-Pagan The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins J Hepatol 58 2013 98 103
33. Y.T. Tsan, C.H. Lee, W.C. Ho, M.H. Lin, J.D. Wang, and P.C. Chen Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection J Clin Oncol 31 2013 1514 1521
34. A. Yamaguchi, S. Tazuma, T. Nishioka, W. Ohishi, H. Hyogo, and S. Nomura Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver Dig Dis Sci 50 2005 1361 1371
35. S.B. Kapadia, and F.V. Chisari Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids Proc Natl Acad Sci U S A 102 2005 2561 2566
36. G.A. Rao, and P.K. Pandya Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C Gastroenterology 140 2011 144 152
37. L. Delang, J. Paeshuyse, I. Vliegen, P. Leyssen, S. Obeid, and D. Durantel Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development Hepatology 50 2009 6 16
38. M. Atsukawa, A. Tsubota, C. Kondo, N. Itokawa, Y. Narahara, and K. Nakatsuka Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b J Gastroenterol Hepatol 28 2013 51 56
39. T. Bader, J. Fazili, M. Madhoun, C. Aston, D. Hughes, and S. Rizvi Fluvastatin inhibits hepatitis C replication in humans Am J Gastroenterol 103 2008 1383 1389
40. S.S. Kim, L.F. Peng, W. Lin, W.H. Choe, N. Sakamoto, and N. Kato A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication Gastroenterology 132 2007 311 320
41. T. Bader, L.D. Hughes, J. Fazili, B. Frost, M. Dunnam, and A. Gonterman A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naive genotype 1 hepatitis C patients J Viral Hepat 20 2013 622 627
42. C. Kondo, M. Atsukawa, A. Tsubota, N. Itokawa, T. Fukuda, and Y. Matsushita An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin J Viral Hepat 19 2012 615 622
43. E. Georgescu, D. Catu, R.M. Stoica, and R.I. Ionescu Fluvastatin as out-of-label enhancer for early (EVR) and sustained (SVR) virological response in chronic hepatitis C treated with peginterferon and ribavirin J Hepatol 52 2010 S110
44. J. Dimitroulakos, I.A. Lorimer, and G. Goss Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway Clin Cancer Res 12 2006 4426s 4431s
45. T.T. Zhao, B.G. Le Francois, G. Goss, K. Ding, P.A. Bradbury, and J. Dimitroulakos Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins Oncogene 29 2010 4682 4692
46. J. Lupberger, M.B. Zeisel, F. Xiao, C. Thumann, I. Fofana, and L. Zona EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy Nat Med 17 2011 589 595
47. B.C. Fuchs, Y. Hoshida, T. Fujii, L. Wei, S. Yamada, and G.Y. Lauwers Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma Hepatology. 59 2014 1577 1590
48. C. Zafra, J.G. Abraldes, J. Turnes, A. Berzigotti, M. Fernandez, and J.C. Garca-Pagan Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis Gastroenterology 126 2004 749 755
49. J.G. Abraldes, A. Albillos, R. Banares, J. Turnes, R. Gonzalez, and J.C. Garcia-Pagan Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial Gastroenterology 136 2009 1651 1658